Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 9:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 254 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Maximum Tolerated Dose Clear all

Conditions: Prostate Cancer
Interventions: Lenalidomide, Docetaxel, Prednisone; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 2
States / cities: New York, New York

Conditions: Peripheral T-cell Lymphoma
Interventions: Belinostat, CHOP; Drug
Lead sponsor: Acrotech Biopharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 8
States / cities: New Haven, Connecticut • Athens, Georgia • Rochester, Minnesota + 5 more

Conditions: Sarcoma, Neuroblastoma, Wilms Tumor, Leukemia, Lymphoma, Brain Tumors
Interventions: Marqibo; Drug
Lead sponsor: Acrotech Biopharma Inc.; Industry
Eligibility: 2 Years to 20 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neoplasms
Interventions: Rogaratinib (BAY1163877) oral solution, Rogaratinib (BAY1163877) oral tablet, Rogaratinib (BAY1163877) 800 mg BID; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 3
States / cities: Chicago, Illinois • Pittsburgh, Pennsylvania

Conditions: Neoplasm
Interventions: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg, HCC Child-Pugh A expansion cohort: Regorafenib 100 mg, HCC Child-Pugh B expansion cohort: Regorafenib 100 mg, NSCLC expansion cohort: Regorafenib 100 mg; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 5
States / cities: Los Angeles, California • Aurora, Colorado • Houston, Texas + 1 more

Conditions: T-Cell Peripheral Lymphoma, Gamma Delta Hepatosplenic T-Cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, NK T-Cell Lymphoma
Interventions: Rituximab, Etoposide, Siplizumab, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Burn Injury
Interventions: SN514-066b; Biological
Lead sponsor: SERDA bv; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Leukemia, Myeloid, Myelodysplastic Syndromes
Interventions: Lenalidomide; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Solid Tumors, Multiple Myeloma, Non-Hodgkins Lymphoma, Pancreatic Neuroendocrine Tumors, PNET, NHL
Interventions: DCR-MYC; Drug
Lead sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 6
States / cities: Stanford, California • Chicago, Illinois • Boston, Massachusetts + 3 more

Conditions: Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Interventions: Everolimus, Nelarabine, Cyclophosphamide, Etoposide; Drug
Lead sponsor: Emory University; Other
Eligibility: 2 Years to 29 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 4
States / cities: Atlanta, Georgia • New York, New York • Cincinnati, Ohio + 1 more

Conditions: Medical Oncology
Interventions: BAY1217389, Paclitaxel; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 6
States / cities: Santa Monica, California • Denver, Colorado • New Haven, Connecticut + 3 more

Conditions: Tumors, Lymphoma, Multiple Myeloma
Interventions: ridaforolimus; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Ovarian Cancer
Interventions: CC-5013, liposomal doxorubicin; Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 5
States / cities: San Francisco, California • Orlando, Florida • New York, New York + 2 more

Conditions: Carcinoma, Small Cell, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Mesothelioma
Interventions: Depsipeptide, Flavopiridol (alvocidib); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Glioblastoma Multiforme
Interventions: TPI 287, Bevacizumab; Drug
Lead sponsor: Cortice Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 9
States / cities: Birmingham, Alabama • St Louis, Missouri • Hackensack, New Jersey + 6 more

Conditions: Neoplasms
Interventions: Roniciclib (BAY1000394); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 3
States / cities: St Louis, Missouri • Buffalo, New York • Cleveland, Ohio

Conditions: Medical Oncology
Interventions: BAY1161909, Paclitaxel; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 6
States / cities: Santa Monica, California • New Haven, Connecticut • Boston, Massachusetts + 3 more

Conditions: Breast Cancer
Interventions: SC-005; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 8
States / cities: Chicago, Illinois • St Louis, Missouri • New York, New York + 4 more

Conditions: Leptomeningeal Metastasis
Interventions: 186RNL; Drug
Lead sponsor: Cerenome; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 6
States / cities: Chicago, Illinois • Manhasset, New York • New York, New York + 3 more

Conditions: Renal Cell Carcinoma, Hereditary Leiomyomatosis, Renal Cell Cancer
Interventions: Vandetanib, Metformin, Vandetanib/Metformin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neoplasms
Interventions: BAY 1238097; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hepatocellular Carcinoma
Interventions: PDR001, Sorafenib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Neoplasms, Advanced Solid Tumor
Interventions: briciclib; Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: Aurora, Colorado • Buffalo, New York • Nashville, Tennessee

Conditions: Leukemia, Myeloid, Acute
Interventions: BAY1436032; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 8
States / cities: Buffalo, New York • New York, New York • The Bronx, New York + 4 more

Search by objective public record fields.

Study of Lenalidomide and Docetaxel in Subjects With Androgen Independent Prostate Cancer

Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)

To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

SN514-066b Enzyme in Deep Partial Thickness Burns

Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease

Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma

Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma

Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel

Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)

Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma

Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum

Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies

Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel

A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)

Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma

BAY1238097, First in Man

Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients

Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors

BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)